Siren L.L.C. Has $64.97 Million Stake in Stoke Therapeutics, Inc. $STOK

Siren L.L.C. lowered its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 11.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,995,347 shares of the company’s stock after selling 252,000 shares during the quarter. Stoke Therapeutics accounts for approximately 1.8% of Siren L.L.C.’s portfolio, making the stock its 16th largest position. Siren L.L.C.’s holdings in Stoke Therapeutics were worth $64,968,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of STOK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after acquiring an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after purchasing an additional 293,072 shares during the period. Jane Street Group LLC increased its stake in Stoke Therapeutics by 125.2% in the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after purchasing an additional 15,001 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Stoke Therapeutics by 26.6% in the second quarter. JPMorgan Chase & Co. now owns 25,655 shares of the company’s stock valued at $291,000 after purchasing an additional 5,398 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Stoke Therapeutics by 33.9% during the second quarter. Rhumbline Advisers now owns 66,419 shares of the company’s stock valued at $754,000 after purchasing an additional 16,820 shares during the period.

Stoke Therapeutics Trading Up 2.4%

NASDAQ STOK opened at $29.65 on Friday. The company has a fifty day simple moving average of $30.42 and a 200 day simple moving average of $32.17. Stoke Therapeutics, Inc. has a 12-month low of $12.25 and a 12-month high of $40.22. The company has a market cap of $1.85 billion, a P/E ratio of -10.55 and a beta of 1.17.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The firm had revenue of $6.23 million for the quarter, compared to the consensus estimate of $6.48 million. Sell-side analysts predict that Stoke Therapeutics, Inc. will post -3.22 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. The Goldman Sachs Group initiated coverage on Stoke Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $44.00 target price for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 11th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $43.00.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 1,795 shares of Stoke Therapeutics stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the transaction, the insider directly owned 34,826 shares in the company, valued at $1,064,979.08. This trade represents a 4.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the sale, the general counsel directly owned 18,086 shares of the company’s stock, valued at approximately $541,675.70. The trade was a 7.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is owned by company insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.